More Neuroscientific Biopharmaceuticals Ltd. news
Neuroscientific Biopharmaceuticals Ltd.ASX: NSB

Final Report received for Glaucoma Study

May 4, 2020 at 12:22 AM EDT · Issued by Neuroscientific Biopharmaceuticals Ltd.

Filed with ASX · May 4, 2020 at 12:22 AM EDT

On 6ix: 6ix.com/news/final-report-received-for-glaucoma-study

Neuroscientific Biopharmaceuticals Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Neuroscientific Biopharmaceuticals Ltd. on 6ix

Story so far

  • Positive Results in Glaucoma Pig ModelMar 11, 2020
  • EmtinB Can Become a Revolutionary Treatment for GlaucomaOct 1, 2019

Earlier from Neuroscientific Biopharmaceuticals

  • Positive Results in MS StudyMar 17, 2020
  • Positive Results in Glaucoma Pig ModelMar 10, 2020
  • Additional US Patent grantedJan 21, 2020
  • CVN Model Indicates Neuroprotective Properties of EmtinBDec 5, 2019
  • NSB - Company UpdateDec 1, 2019

Later from Neuroscientific Biopharmaceuticals

  • EmtinB Positive Results in MSJul 13, 2020
  • Full Report from Multiple Sclerosis StudyAug 3, 2020
  • Updated Appendix 4CAug 11, 2020
  • Appendix 4E and Annual ReportAug 28, 2020
  • Strategic Placement to AlphaSwiss PartnersNov 11, 2020
All Neuroscientific Biopharmaceuticals news releases↗

Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.

Follow Neuroscientific Biopharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer